About

Investors and Funding

Investors

Why invest in Atlas

Atlas Molecular Pharma’s business model is to exploit its innovative, cutting-edge and proprietary platform technology approach, which combined with the expertise of its highly skilled and experienced team will deliver candidate drugs for patients suffering from devastating rare and ultra-rare diseases.

Our de-risked strategy will create value by delivering candidate drugs for multiple diseases suitable for pre-clinical and clinical licensing to larger Biotech and Pharma partners, positioning Atlas Molecular Pharma as a “Partner of Choice”.

Additional upside will be created by continuing to build a proprietary chemical resource/“drug discovery engine” suitable for forming potential collaborations/alliances with Biotech and Pharma partners.

  • Arquimea Group
  • Kereon Partners
  • CRB Inverbío
  • Inveready
  • CIC bioGUNE
  • Grupo SPRI
  • CDTI
  • Endometrial DIDI

Funding

Funded Projects

ATLAS’s pipeline is supported by competitive and non-dilutive funding.

PROGRAMA DE AYUDAS DE APOYO A LA I+D EMPRESARIAL – HAZITEK. Actuación cofinanciada por el Gobierno Vasco y la Union Europea a través del fondo europeo de desarrollo regional 2021-2027 (FEDER). Proyecto CICLOATL; Desarrollo clínico avanzado y optimización farmacéutica de chaperonas farmacológicas alostéricas para el tratamiento de la Porfiria Eritropoyética Congénita. Presupuesto aceptado 2026 €120,555.34; Subvención concedida €36,166.61.

AEI / NextGenerationEU-PRTR (ref. CPP2023-010742). Evaluation of the efficacy of an oral formulation of ciclopirox for the treatment of congenital erythropoietic porphyria. €364,943.45

AEI / NextGenerationEU-PRTR (ref. CPP2022-009738). Development of a new pharmacological chaperone treatment for hereditary tyrosinemia type I (ATL-002). €579,292.80

AEI / NextGenerationEU-PRTR (ref. CPP2021-008581). Development of an oral formulation of ciclopirox for the treatment of congenital erythropoietic porphyria. €913,115.30

NEURO-COOP (ref. EFA031/01). Interreg VI-A Spain-France-Andorra programme (POCTEFA 2021-2027), co-financed at 65% by the EU. Total budget €1,824,070.45; FEDER funding €1,185,645.78.

European Commission – Contract Number [101119492]. Marie Sklodowska-Curie Action (MSCA) Doctoral Network (DN) HORIZON-MSCA-2022-DN-01. Project ENSCC; European Network on the Supramolecular Chemistry of Carbohydrates. €251,971.20

European Commission – Contract Number [956758]. Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks (ITN) H2020-MSCA-ITN-2020. GLYTUNES; A multidisciplinary training network for the bioinspired development of glycomimetics tuning the Siglec-Sialoglycan axis. €250,904.88

Programa BIKAINTEK 2020. Actuación financiada por el Departamento de Desarrollo Económico, Sostenibilidad y Medio Ambiente del Gobierno Vasco. Ayudas para el desarrollo de proyectos de I+D mediante la contratación de personas doctoradas y la realización de Doctorados Industriales. Subvención concedida: €70,298.00.

REDPRION (ref. EFA148/16). Interreg V-A Spain-France-Andorra programme (POCTEFA 2014-2020), co-financed at 65% by the EU. Total budget €1,999,849.96; FEDER funding €1,299,902.45.

NEOTEC – SNEO-20161356.